Novel Neurodegenerative Therapies for Tinnitus

Tinnitus, the perception of sound without an external source, affects millions worldwide. Its persistence stems not from the ear, but from lasting changes within the brain. A 2026 review by J L Liu and Peng Liu proposes that these changes share a core biology with neurodegenerative diseases like Alzheimer’s and Parkinson’s. The authors argue that repurposing therapies developed for neurodegeneration could offer a new, mechanism-based path for tinnitus treatment.

Shared Mechanisms: Neuroinflammation and Excitotoxicity

The Liu review systematically identifies three overlapping mechanisms. First is neuroinflammation. In response to injury or stress, such as loud noise exposure or hearing loss, immune-like cells in the brain (glia) become activated. They release inflammatory signals that can alter how neurons function and communicate, potentially stabilizing the hyperactive neural circuits believed to generate tinnitus.

A second key process is glutamate-mediated excitotoxicity. Glutamate is the brain’s primary excitatory chemical messenger. In excess, it can overstimulate neurons, leading to damage and dysfunctional synaptic transmission. This excitotoxic state is a hallmark of both neurodegenerative disease and models of tinnitus. It may contribute to the increased central gain observed in hyperacusis and tinnitus, where the brain amplifies incoming sound signals abnormally.

The third area is synaptic dysfunction and aberrant network reorganization. Healthy brain circuits rely on precise, adaptable connections. Tinnitus and neurodegeneration both involve a breakdown in this plasticity, leading to maladaptive patterns. In tinnitus, this can manifest as thalamocortical dysrhythmia, a disruption in the rhythmic communication between brain regions that underlies persistent phantom perceptions.

Repurposing Neurodegeneration Therapies: Three Key Approaches

Based on these shared mechanisms, the review evaluates specific therapeutic strategies.

Targeting Neuroinflammatory Cascades

Drugs that suppress chronic brain inflammation are under investigation for Alzheimer’s disease. In animal models of tinnitus, similar anti-inflammatory agents have shown promise. They can reduce the production of inflammatory cytokines and dampen glial cell activation, leading to a decrease in tinnitus-like behaviors. This suggests that calming the brain’s immune response could help reset dysfunctional auditory circuits.

Modulating Neurotrophic Factors

Neurotrophic factors, like BDNF (brain-derived neurotrophic factor), are proteins that support neuron survival, growth, and synaptic plasticity. In neurodegeneration, their delivery is impaired. In tinnitus, their regulation may be altered, contributing to maladaptive changes. Strategies to boost or normalize these factors—through drugs or even certain sound therapies—could promote healthier neural rewiring. This concept of supporting cellular health aligns with research on engram cell reprogramming for cognitive longevity.

Mitigating Glutamate Excitotoxicity

Several drugs developed for neurological conditions aim to modulate glutamate receptors or clear excess glutamate. Preclinical tinnitus studies using these compounds report reductions in neural hyperactivity and behavioral signs of tinnitus. This direct approach to calming overexcited neurons addresses a core proposed driver of the condition.

Current Evidence: From Animal Models to Human Trials

The evidence compiled by Liu and Liu comes primarily from controlled animal studies. These models allow researchers to observe changes in brain biology and behavior—such as a reduced startle response to silent gaps—after administering candidate drugs. The findings are consistent, showing that intervening in these shared pathways can alter tinnitus outcomes.

Translation to human clinical trials, however, is just beginning. Some early-phase trials are testing drugs with anti-inflammatory or neuroprotective properties for tinnitus. The outcomes are not yet definitive, but the rationale is strong. A significant challenge is that tinnitus is a subjective experience, requiring sophisticated biomarkers and patient-reported measures to assess treatment efficacy.

Practical Implications and Future Directions

For patients and clinicians, this research offers a new framework for understanding tinnitus. It positions the condition not as a mere ear problem, but as a disorder of brain health involving specific, modifiable biological processes. This could shift the therapeutic focus toward neuroprotection and circuit stabilization.

Future work needs to identify which patients have tinnitus driven predominantly by inflammation, excitotoxicity, or synaptic dysfunction. Personalized treatment could then follow. The review also highlights the need for more human trials combining these drug approaches with established behavioral therapies, like coordinated reset stimulation or cognitive behavioral therapy, which can address the perceptual and emotional components of tinnitus.

By bridging auditory neuroscience and neurodegeneration research, the Liu review provides a cohesive scientific argument for exploring repurposed drugs. It moves the field toward mechanism-based interventions that target the root brain dysfunctions maintaining tinnitus.

Source: Liu JL, Liu P. (2026). Repurposing Neurodegeneration Therapies for Tinnitus: A Mechanistic Review. Front Aging Neurosci. 10.3389/fnagi.2026.1835649.